Basel, Switzerland (UroToday.com) During the Molecular Biomarkers and Novel Imaging in Advanced Prostate Cancer session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Dr. Rosalind Eeles discussed how patients should be selected for genetic counseling and testing. In her opinion, there are several important questions: What is the spectrum of genetic predisposition that we currently […]
Basel, Switzerland (UroToday.com) Dr. Mack Roach presented on radiotherapy options for patients with clinical node-positive prostate cancer. The talk began with trying to define the optimal candidate for salvage lymph node dissection (SLND) for nodal recurrence of prostate cancer. Fossati et al.1 published a study that included 654 patients who experienced prostate-specific antigen (PSA) rise and nodal […]
Basel, Switzerland (UroToday.com) At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 meeting, Dr. Johann De Bono continued the Molecular Biomarkers and Novel Imaging in Advanced Prostate Cancer (APC) session with a high-level discussion of the clinical utility of molecular markers. Dr. De Bono notes that there are many biomarker classes, but the current talk focuses […]
Basel, Switzerland (UroToday.com) Colin Pritchard, MD from the University of Washington kicked off the Molecular Biomarkers and Novel Imaging in advanced prostate cancer (APC) session at the Advanced Prostate Cancer Consensus Conference (APCCC), discussing the state of the art of molecular characterization in advanced prostate cancer. He notes that there is an emerging model for advanced disease, […]
Automated bone scan index (aBSI) change (ΔBSI) after treatment and survival in men with prostate cancer remains unclear. We evaluated the correlation between ΔBSI after cabazitaxel and overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (CRPC). We retrospectively enrolled 32 men with bone metastatic CRPC who had received cabazitaxel. The correlation between […]
To determine the utility of 18F-sodium fluoride positron emission tomography-computed tomography (18F-NaF PET/CT) in the imaging assessment of therapy response in men with osseous-only metastatic prostate cancer. In this Institutional Review Board-approved single institution retrospective investigation, we evaluated 21 18F-NaF PET/CT scans performed in 14 patients with osseous metastatic disease from prostate cancer and no […]
To evaluate the prognostic value of pretreatment plasma systemic immune-inflammation index (SII), albumin, and fibrinogen levels in metastatic castration-resistant prostate cancer (mCRPC) patients treated with first-line docetaxel and to screen out the patients with the greatest risk for poor prognosis. The plasma SII, albumin, and fibrinogen levels were examined before treatment and analyzed with patient […]
Radical cystectomy (RC) is a challenging procedure with significant morbidity, though remains the standard of care treatment for many patients with bladder cancer. There has been debate regarding the utility of universal risk calculators to aid in point-of-care prediction of complications in individual patients preoperatively. We retrospectively evaluated the predictive value of the ACS NSQIP […]
An 85-year-old male patient receiving hormone therapy for prostate cancer and secondary open-angle pseudoexfoliation glaucoma developed peripheral choroidal detachment in both eyes. The patient had been admitted to the eye hospital for clarification of a vascular occlusion in the left eye. Cerebral magnetic resonance imaging could exclude metastases and a cerebral space-occupying lesion as the […]
There are only a few studies on characteristics and outcomes of late recurrence (LR) of urothelial carcinoma of bladder (UCB) after radical cystectomy (RC). The objective of this study was to assess characteristics and oncological outcomes of such LR that developed 5 years after RC. We retrospectively reviewed 570 patients who underwent RC and bilateral […]
